24078-79-3

Basic information

• Product Name: 2-Furancarbonyl chloride, 5-chloro-
• Synonyms: 5-chloro-furan-2-carboxylic acid chloride;5-chlorofuroyl chloride;2-Furancarbonyl chloride,5-chloro;5-Chlor-furan-2-carbonylchlorid;5-Chlor-fur-2-oylchlorid;5-Chlorofuran-2-carbonylchlorid;5-chloro-furan-2-carbonyl chloride
• CAS NO: 24078-79-3
• Molecular Formula: C5H2Cl2O2
• Molecular Weight: 164.976
• Mol File: 24078-79-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 192.2±20.0 °C(Predicted)
• Density: 1.491±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-Furancarbonyl chloride, 5-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Furancarbonyl chloride, 5-chloro-(24078-79-3)
• EPA Substance Registry System: 2-Furancarbonyl chloride, 5-chloro-(24078-79-3)

Safety Data

• Hazardous Substances Data: 24078-79-3(Hazardous Substances Data)

Usage

Description

2-Furancarbonyl chloride, 5-chlorois an organic compound with the molecular formula C5H2ClO2. It is a derivative of furancarbonyl chloride, featuring a chlorine atom at the 5th position. 2-Furancarbonyl chloride, 5-chlorois known for its reactivity and is commonly utilized in the synthesis of various pharmaceutical compounds.

Uses

Used in Pharmaceutical Synthesis:
2-Furancarbonyl chloride, 5-chlorois used as a reagent in the pharmaceutical industry for the preparation of JNK inhibitors. These inhibitors play a crucial role in regulating the JNK signaling pathway, which is involved in various cellular processes, including cell growth, differentiation, and apoptosis. By modulating the JNK pathway, these inhibitors can potentially be used to treat a range of diseases, including cancer and neurodegenerative disorders.
Additionally, 2-Furancarbonyl chloride, 5-chlorois also used in the synthesis of 2'-aminoanilide inhibitors of cFMS tyrosine kinase. These inhibitors are considered potential anti-inflammatory agents, as they can help regulate the activity of cFMS tyrosine kinase, a key enzyme involved in the inflammatory response. By targeting this enzyme, these inhibitors may provide a novel approach to managing inflammation-related conditions, such as arthritis and autoimmune diseases.

Upstream product

• 527-69-5 2-furancarbonyl chloride 
• 21508-19-0 5-chloro-2-furaldehyde 
• 618-30-4 5-chlorofuran-2-carboxylic acid 
• 79-37-8 oxalyl dichloride 

Downstream Products

• 21508-19-0 5-chloro-2-furaldehyde 
• 618-30-4 5-chlorofuran-2-carboxylic acid 
• 1173834-64-4 C₁₉H₂₁ClN₂O₄ 
• 111252-98-3 3t-(5-chloro-[2]furyl)-acrylic acid 
• 91498-60-1 1-(5-chloro-[2]furyl)-ethanone-(2,4-dinitro-phenylhydrazone) 
• 103987-69-5 5-chloro-furfural-(2,4-dinitro-phenylhydrazone) 
• 583052-89-5 5-chlorofuran-2-carboxylic acid benzylamide 
• 82366-66-3 1-(5-chlorofuroyl)-3-phenylthiourea 

Relevant articles and documents

Synthesis of N-methylpyridine-chlorofuranformamide analogs as novel OPG up-regulators and inhibitors of RANKL-induced osteoclastogenesis

The OPG/RANKL/RANK pathway is a promising target for the design of therapeutic agents used in the treatment of osteoporosis. E09241 with an N-methylpyridine-chlorofuranformamide structural skeleton was previously identified to decrease bone loss and thus protect against osteoporosis in ovariectomized rats through increasing osteoprotegerin (OPG) expression. In this study, 36 derivatives of E09241 (3a) were prepared. The synthesis, up-regulation of OPG activities, SAR (structure–activity relationship), and cytotoxicity of these compounds are presented. Compounds with good up-regulating OPG activities could inhibit RANKL (the receptor activator of nuclear factor-kappa B ligand)-induced osteoclastogenesis in RAW264.7 cells. Particularly, compounds 3c and 3i1 significantly reduced NFATc1 and MMP-9 protein expression through inhibition of the NF-κB and MAPK pathways in RANKL induced RAW264.7 cells. In addition, compounds 3c and 3v significantly promoted osteoblast differentiation in MC3T3-E1 cells in osteogenic medium, and compounds 3c, 3v, and 3i1 obviously increased OPG protein expression and secretion in MC3T3-E1 cells. Furthermore, the pharmacokinetic profiles, acute toxicity, and hERG K+ channel effects of compounds 3a, 3c, 3e, 3v, and 3i1 were investigated. Taken together, these results indicate that N-methylpyridine-chlorofuranformamide analog 3i1 could serve as a promising lead for the development of new agents for treating osteoporosis.

NICOTINIC ACETYLCHOLINE RECEPTORSUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES

Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteoraryl carboxylic acids and certain diazabicycloalkanes. The

Aroylthioureas: New organic ionophores for heavy-metal ion selective electrodes

Thiourea derivatives (46 aroylthioureas) having different substituents close to the sulfur atom were synthesized and their ionophore potential in ion selective electrodes (ISEs) was examined. Structural considerations were taken into account based on the corresponding heavy-metal ISE parameters. As ionophores, some 1-furoyl-3-substitnted thioureas (series 2) gave the best results in Pb(II), Hg(II) and Cd(II) ISEs. The strong intramolecular hydrogen bond in series 2 allows ligand interaction only through the C=S group. Substituents on the furan and phenyl rings give rise to low solubility in the membrane plasticizer. 3-Alkyl substituted furoylthioureas improve solubility but enhance oxidative processes with chain length. New X-ray diffraction (XRD) structures and theoretical DFT calculations were considered in the analysis of the substituent influence on the selectivity of ISEs. These new ionophores have advantages because of their stability, simple synthesis and easy modification of the sulfur binding ability resulting from substitution.